Ask AI

Optimizing CAR T-Cell Therapy in Multiple Myeloma: Practical Insights on Patient Selection, Bridging, and Sequencing

Clinical Thought
Clinical Thought

Released: November 20, 2026

See Activity Collection

CAR T-cell therapy has transformed the treatment landscape for patients with relapsed/refractory multiple myeloma. As these therapies move earlier in the treatment course, healthcare professionals have an opportunity to improve outcomes for more patients. In this ClinicalThought, expert faculty share practical insights from clinical trials and real-world experience, including strategies for optimizing outcomes in older patients and those with high-risk disease or comorbidities. They also explore how emerging bispecific antibody combinations may influence treatment sequencing and highlight the importance of collaboration between community and academic centers to support patients throughout the CAR T-cell therapy journey.

CART Conversations CT


CAR T-cell therapy has changed how we treat patients with relapsed/refractory (R/R) multiple myeloma (MM), and we are now seeing the benefits of using it earlier in the treatment course. But knowing when to offer CAR T-cell therapy, which patients are the best candidates, and how to prepare them for treatment is not always straightforward. In our practices, we have found that getting the timing right, choosing an effective bridging strategy, and working closely with our community and academic colleagues can make a meaningful difference in patient outcomes.

Patient Selection: Looking Beyond Age and Comorbidities

Surbhi Sidana, MD:
One of the most important messages I want to emphasize is that more patients may be eligible for CAR T-cell therapy than many healthcare professionals (HCPs) realize. Historically, eligibility for autologous stem cell transplantation has influenced how HCPs assess patients for intensive therapies. However, CAR T-cell therapy is a different treatment approach, and I would not assume that patients who are ineligible for transplantation are also ineligible for CAR T-cell therapy.

In my practice, I have treated older patients and individuals with renal impairment or other comorbidities. In our real-world analysis across 15 US Myeloma Immunotherapy Consortium centers, patients with R/R MM received standard-of-care BCMA-directed CAR T-cell therapy with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). Response rates and key treatment-related toxicities were similar between patients aged 75 years and older and propensity-matched younger patients. Similarly, our research evaluating ide-cel in patients with renal impairment demonstrated comparable efficacy, although these patients experienced more early cytopenias.

For me, these findings reinforce the importance of individualized assessments rather than excluding patients based on age or renal function alone.

Doris K. Hansen, MD:
I agree that age is not necessarily an exclusion criterion for CAR T-cell therapy. I have successfully treated older patients, including those with significant comorbidities. What matters is understanding each patient's underlying health conditions and anticipating the support they may need throughout treatment. For example, when treating patients receiving dialysis, I generally favor administering CAR T-cell therapy in the inpatient setting. This allows closer monitoring, coordinated nephrology care, and timely management of complications.

I believe the question should be how I can safely deliver CAR T-cell therapy to an individual patient, rather than whether age or a particular comorbidity automatically excludes them.

Earlier CAR T-Cell Therapy: Why Timing Matters

Surbhi Sidana, MD:
The phase III CARTITUDE-4 and KarMMa-3 trials provide compelling evidence supporting CAR T-cell therapy earlier in the RRMM treatment course.

In KarMMa-3, ide-cel improved progression-free survival (PFS) compared with standard-of-care regimens in patients with R/R MM who had received 2-4 prior lines of therapy and were refractory to their most recent regimen.

Similarly, in CARTITUDE-4, cilta-cel improved PFS compared with standard-of-care regimens in patients with lenalidomide-refractory R/R MM who had received 1-3 prior lines of therapy. The PFS benefit was also observed in patients with high-risk disease.

To me, these data are very convincing that we should not wait until later lines of therapy to offer CAR T-cell therapy. Patients may become ineligible as their disease progresses or their health declines and we are likely to have attrition. I therefore believe patients should be referred for CAR T-cell therapy when they first become eligible, even if they ultimately choose another treatment option.

Doris K. Hansen, MD:
I particularly favor earlier CAR T-cell therapy for patients with high-risk disease. These patients often experience shorter response durations regardless of treatment modality, and delaying an effective treatment may limit their opportunities. I also consider whether patients might benefit from additional strategies, such as maintenance or consolidation therapy, although these approaches remain under investigation. My goal is to offer an effective therapy early enough that patients can derive the greatest possible benefit.

Bridging Therapy: Optimizing Efficacy and Safety

Surbhi Sidana, MD:
Bridging therapy is not simply a way to keep disease stable while CAR -T cells are manufactured. We are increasingly recognizing that achieving a meaningful response before infusion may improve both efficacy and safety of CAR-T cells.

An important distinction is the difference between holding therapy, administered before leukapheresis, and bridging therapy, administered after T-cell collection. Before leukapheresis, I generally avoid treatments that could compromise T-cell fitness, particularly bispecific antibodies and intensive alkylating agents. After collection, we have greater flexibility to select effective disease-directed treatment.

In our real-world consortium data involving more than 700 patients receiving cilta-cel, patients who did not respond to bridging therapy experienced higher rates of nonrelapse mortality and parkinsonian-like neurotoxicity. Consequently, I increasingly approach CAR T-cell therapy as a consolidative strategy, aiming to reduce disease burden before infusion. Although a partial response may represent a minimum target, I strive for a very good partial response or deeper whenever feasible.

For heavily pretreated patients, the GPRC5D-targeted bispecific antibody talquetamab offers an important bridging option before BCMA-directed CAR T-cell therapy. In our consortium experience, talquetamab bridging produced a response rate of approximately 71%, with responses deepening after CAR T-cell infusion.

Doris K. Hansen, MD:
My approach to bridging therapy is very similar. I generally aim for a very good partial response or deeper before proceeding with CAR T-cell therapy infusion. If achieving that response requires 2 or 3 cycles of bridging therapy, I believe it can be appropriate to delay infusion in a carefully selected patient.

The goal is to achieve the best possible disease control before CAR T-cell therapy while balancing the risks of additional treatment and disease progression.

Treatment Sequencing: Preserving Future Options

Doris K. Hansen, MD:
As the number of effective immunotherapies increases, treatment sequencing becomes more complex. Earlier use of CAR T-cell therapy may offer several advantages, including improved T-cell fitness, lower disease burden, and more effective bridging options.

Real-world evidence suggests that prior BCMA-directed therapy can reduce subsequent CAR T-cell efficacy in heavily pretreated patients. For this reason, I generally favor CAR T-cell therapy earlier in the treatment course when clinically appropriate.

However, treatment sequencing is evolving rapidly as bispecific antibody combinations demonstrate promising efficacy earlier in the disease course.

Phase III data also support the use of bispecific antibody combinations earlier in the disease course. MajesTEC-3 (NCT05083169) evaluated the BCMA-directed bispecific antibody teclistamab plus daratumumab in patients with R/R MM who had received 1-3 prior lines of therapy. Estimated 36-month PFS was 83.4% with teclistamab plus daratumumab vs 29.7% with daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) (HR: 0.17).

MonumenTAL-3 (NCT05455320) evaluated the GPRC5D-directed bispecific antibody talquetamab plus daratumumab, with or without pomalidomide, in patients with R/R MM who had received at least 1 prior line of therapy. At the interim analysis, estimated 24-month PFS was 81.3% with talquetamab plus daratumumab and pomalidomide, 77.6% with talquetamab plus daratumumab, and 51.2% with DPd. The HRs for progression or death vs DPd were 0.28 and 0.33, respectively.

These combinations have also demonstrated encouraging efficacy, further expanding treatment options for patients earlier in the disease course. As these therapies become available in earlier lines, I believe additional data will be essential to determine how best to sequence bispecific antibodies and CAR T-cell therapy while preserving T-cell fitness and maximizing long-term outcomes.

I believe additional prospective evidence will be essential to determine the optimal sequence of these treatments, particularly as bispecific antibodies become available earlier in the disease course.

Surbhi Sidana, MD:
My personal preference is to use CAR T-cell therapy before BCMA-directed bispecific antibodies whenever possible. One reason is that continuous bispecific antibody exposure may contribute to T-cell dysfunction, potentially affecting subsequent CAR T-cell manufacturing and efficacy. I also consider that bispecific antibodies can remain effective after CAR T-cell therapy, allowing patients to benefit from both treatment approaches.

Toxicity Management Requires Long-term Collaboration

Doris K. Hansen, MD:
Successful CAR T-cell therapy extends well beyond infusion. Although HCPs are familiar with acute toxicities such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS), I believe delayed complications deserve increasing attention.

These include prolonged cytopenias, infections, hypogammaglobulinemia, non-ICANS neurologic toxicities, and immune effector cell (IEC)–associated enterocolitis.

For example, parkinsonian-like neurotoxicity (referred to as IEC-parkinsonism) may present with bradykinesia, rigidity, tremors, or gait abnormalities. Enterocolitis may emerge several months after infusion and present with severe, persistent, and nonbloody diarrhea.

Early recognition and prompt multidisciplinary evaluation are essential. The International Myeloma Working Group has developed living guidelines to support HCPs in recognizing and managing these complications.

I also want to emphasize the importance of community HCPs in long-term monitoring, infection prevention, immunoglobulin replacement, and timely communication with the treating CAR T-cell therapy center. Patients often transition between academic and community settings, making coordinated care essential throughout the treatment journey.

Moving Forward: Making CAR T-Cell Therapy More Accessible

Surbhi Sidana, MD:
As CAR T-cell therapy becomes an increasingly important component of MM care, I believe the greatest opportunity lies in identifying eligible patients earlier and optimizing their treatment before infusion. I encourage referring HCPs to connect with CAR T-cell therapy programs early, even before a patient has undergone formal evaluation. These conversations can help guide treatment selection and preserve future options.

Doris K. Hansen, MD:
I believe successful CAR T-cell therapy depends on much more than the infusion itself. It requires thoughtful sequencing, effective supportive care, close toxicity monitoring, and ongoing collaboration between treatment centers. By improving coordination across practice settings, I hope to help more patients safely access these therapies and experience meaningful and durable benefits.

Your Thoughts
How has the expanding role of CAR T-cell therapy changed your approach to managing patients with R/R MM? What challenges do you encounter most frequently with patient selection, bridging therapy, or coordinating care between treatment centers?

Poll

1.

Which aspect of CAR T-cell therapy for patients with R/R MM presents the greatest challenge in your clinical practice?

Submit